TOBI®: DELIVERED TO THE LUNGS WITH MINIMAL SYSTEMIC EXPOSURE1

TOBI achieves high concentrations of antibiotic in the
airways for efficacy against Pa2,3 in CF


Since TOBI is delivered directly to the lungs, there is minimal systemic exposure, unlike parenteral tobramycin1

  • 95% of patients achieved sputum concentrations ≥25 times the MIC of the Pa isolates3
  • Average serum level seen with TOBI 1 hour after dosing is 1.05 μg/mL3
Percentage of CF patients infected with Pa at different age intervals

Background on tobramycin

  • Typical once-daily parenteral dosing would be expected to produce a peak blood level of 25 to 35 μg/mL. The optimum peak serum tobramycin concentration for treatment of lung infections in CF has not been established4
  • With parenteral tobramycin use, the mean peak sputum concentration that can be achieved is usually only 12% to 20% of blood level3
 
Important Safety Information full Prescribing Information www.fda.gov/medwatch

References:

  • Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest. 2001;120:107S-113S.
  • TOBI [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
  • Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002;122:219-226.
  • Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180:802-808.